THAC has been created on the basis of 25 years of research initiated by our CEO, Pr. Christian Bréchot, by a team of experts in complementary fields. The company has been created in 2018, is based in Paris and has a subsidiary in Tampa, Florida. The founders of the company put in place an operational R&D team, experienced consultants, a strategic board as well as medical independent experts to achieve the successful development of our molecule, ALF-5755.

Clinical Strategy

We are developing an innovative therapeutic strategy -ALF-5755- derived from the human HIP/PAP protein to cure age-related diseases linked to insulin resistance such as type II diabetes, non-alcoholic steatohepatitis (NASH) and Alzheimer’s disease.

Board and executives

Our board holds all the scientific, strategic and management skills required to build up a transformative biotech company.

Pr. Christian Bréchot

Co-founder & Executive Chairman

Christian is internationally known as the former head of french institutes (Pasteur institute, Inserm and BioMérieux). He is hepatologist and professor at the university of South Florida.

Dr. Paul Amouyal

Co-founder & Vice-President

Paul is an expert in hepato-gastro-enterology and former head of clinics. He is currently CEO of a biotech company and a board member of several biotechs.

Dr. Gilles Amouyal

Co-founder & Vice-President

Gilles is an expert in hepato-gastro-enterology and former head of clinics. He currently is CSO of a biotech company and a board member of several biotechs.

Pr. Christophe Magnan

Co-founder & Scientific Expert

Christophe is professor at the University of Paris. He is an expert in glucose homeostasis and signed more than 150 scientific papers.

Dr. Lyse Santoro

Chief Executive Officer

Lyse is immunologist and has a strong expertise in the healthcare industry (CEO Magnisense, VP Ipsen, bioMérieux). She was the personal advisor of the French Minister of Research, in charge of Innovation.

Dr. Laure Jamot

Co-founder & COO/CSO

Laure has a strong expertise in clinical trials. She is former head of preclinical and clinical R&D and former head of IP. She participated in 16 clinical trials.

Marc Le Bozec

Co-founder & Fund Manager

Marc is fund manager at Financière Arbevel and masters the financial questions of biotechs. He is in the board of several biotech companies.

R&D team

Our R&D team has a strong expertise in project management and hold all the necessary technical skills.

Aurelie Le Lay

Engineer

Aurélie holds a master of innovative pharmacology, pharmacology and toxicology. She has strong technical skills on cellular biology and physiology and has been involved in different projects focused on diabetes and obesity

Erwann Philippe

Research engineer

Erwann has 10 years of experience as research engineer in public and private laboratories. He is specialized in physiology and has been involved in several projects on diabetes.

Pr. Céline Cruciani

R&D coordinator

Céline is professor at the university of Paris. She brings her knowledge and expertise as scientific project leader to the company.

Dr. Fanny Roth

R&D project manager

Fanny hold a phD in life science. She has a strong knowledge in molecular and cellular biology and an expertise in management of scientific projects

Consulting Experts

THAC is surroundered by a team of clinical and preclinical consulting experts to strenghten its development.

Dr. Michel Thiry

CMC consultant

Michel brings to THAC his expertise in biological process development and manufacturing

Denis Ravel

Preclinical consultant

Denis helps the company to build a strong preclinical program to reach phase II clinical trial.

Strategic board

Together with founders, our strategic board helps to define the best future for THAC

Dr. Jean-Philippe Santoni

Seasoned manager in drug and medical device development

Jean-Philippe brings to THAC his experience in managing pharmaceutical and clinical development.

Pr. Patrick Couvreur

Expert in Chemistry

Patrick is a pharmacist, emeritus professor of Pharmacy at the Paris-Saclay University, member of the Académie des Sciences and holder of the chair of “Innovations Technologiques” at the College de France. He brings to the company all his knowledge and expertise in drug delivery and drug targeting.

Pr. Bernard Thorens

Expert in insulin resistance

Bernard is professor at the university of Lausanne and is an expert in the molecular basis of metabolic diseases, including insulin resistance, obesity and type 2 diabetes.

Clinical experts

Our clinical experts help the company to design the best strategy to bring our molecule from bench to patients

Pr. Jean-François Gautier

Diabetologist

Pr. Jean-François Gautier is professor in diabetology. He brings to THAC its strategic knowledge to settle clinical trials in diabetic patients

Pr. Fabrizzio Andreelli

Diabetologist

Pr. Fabrizzio Andreelli is professor in diabetology. He brings to THAC its strategic knowledge to settle clinical trials in diabetic patients